IL-SURGISPHERE
19.3.2020 15:03:10 CET | Business Wire | Press release
As hospitals start to prepare for a surge in confirmed cases of COVID-19, a more pronounced focus will be placed on the appropriate utilization of healthcare resources. Without planning and organization, this surge can lead to delays in care and wasted resources, both of which hurt patients. In conjunction with public health experts, Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care (https://surgisphere.com/covid-19-triage-tool/ ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005377/en/
Surgisphere leveraged its real time global research network to develop this triage tool. Using its #1 ranked machine learning capabilities, Surgisphere identified the clinical signs and symptoms most predictive of poor outcomes. Using patient age, chronic medical conditions such as cardiovascular disease and diabetes, vital signs, and routine physical exam maneuvers, healthcare professionals on the front line can triage a COVID-19 patient in under a minute.
“This smartphone app will help thousands of vulnerable patients. We have already seen healthcare systems around the world struggling to cope with the extensive number of sick patients. Better triaging them to provide vital healthcare to those who need it the most is a top priority. Our data driven approach combined with advanced machine learning has created a solution that can positively impact healthcare delivery,” said Sapan Desai, MD, PhD, MBA, FACS. Dr. Desai is a vascular surgeon and President and Chief Executive Officer of the Surgisphere Corporation.
This triage tool has been prospectively validated and has a 95.5% overall accuracy. 100% of patients who require immediate attention are correctly triaged. This smartphone app can be accessed at https://www.Surgisphere.com . Surgisphere has also created a COVID-19 mortality risk calculator and diagnosis decision support tool, all freely and immediately available to healthcare professionals around the world.
Surgisphere is currently leveraging its coordinated efforts with global health agencies and its own global network of over 1,200 healthcare organizations to facilitate rapid, world-wide deployment of this life-saving tool. The methodology and results associated with this triage tool have been submitted for peer review and publication in a scientific journal.
Surgisphere is a physician-led company dedicated to making the world a better place, a mission that has motivated its growth and progress since its inception in 2008. An ISO 27001:2013 certified corporation in Chicago, Surgisphere has developed leading solutions in healthcare delivery for patients with kidney disease, cardiovascular disease, lymphedema, and other major diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005377/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain15.9.2026 13:30:00 CEST | Press release
- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over one million Americans. During the 2026 Winter Games in Milano Cortina, Lindsey suffered a serious crash during her downhill race. The fall resulted in multiple injuries that required immediate surgery and several additional procedures. Now, Lindsey is sharing her story and her personal experience treating her moderate-to-severe acute pain with JOURNAVX. “I have experienced countless injuries thro
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
